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Inducible Ca2+-independent nitric
oxide synthase (NOS), also referred to
as NOS2, which is expressed in a variety
of human cancers (1–4), can generate
mutagenic concentrations of nitric oxide
(NO) in mice (5). NOS2 is the most ac-
tive isoform among the three known ni-
tric oxide synthases (6), which also in-
clude the neuronal (NOS1) and
endothelial (NOS3) isoforms. Only
NOS2 is capable of producing sustained
NO concentrations in the micromolar
range (7).
We investigated the hypothesis that
NO generated by NOS2 is capable of
inducing mutations in the p53 (also
known as TP53) gene and contributes to
human colon carcinogenesis. We ana-
lyzed 118 sporadic colon tumors for
NOS2 expression and p53 gene muta-
tions. Colon tumors and surrounding
normal tissues were collected from the
Cooperative Human Tissue Network
and the Department of Pathology, Uni-
versity of Baltimore, with the approval
of local boards governing research on
human subjects, as described previously
(3). The expression of NOS2 was in-
creased in various tumors (Fig. 1, A and
B) throughout the right, left, and sig-
moid colon. Adenomas showed the
highest average NOS2 activity. The
NOS2 activity declined with advancing
tumor stage and was seen at the lowest
level in metastatic tumors (Fig. 1, A).
NOS2 activity correlated with NOS2
protein expression. Immunohistochemi-
cal analysis localized NOS2 protein
mainly in tumor-infiltrating mono-
nuclear cells and less frequently in en-
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Fig. 1. Inducible Ca2+-independent nitric oxide synthase (NOS2) expression in human colon tumors. A)
Ca2+-independent nitric oxide synthase (NOS) activity, characteristic of the type NOS2, is high in colon
adenomas, while it is low in the surrounding normal colon tissues. The activity decreases with the
progression of colorectal cancer (Dukes’ stages A through D) and is lowest in colon carcinoma metastases
in the liver and lung (adenomas: P<.001 and n 4 20; carcinomas: P 4 .01 and n 4 48; both versus
surrounding normal colon tissues from the same patient analyzed by the Wilcoxon signed rank test for
two-tailed, paired analysis). Details of the NOS2 assay, together with the NOS activities for a subset of
the tissues, were reported recently (3). B) Immunohistochemical analysis of colon tumors for NOS2
protein. In panels a and b, focal clusters of tumor cells (arrows) have cytoplasmic staining with brown
chromogen indicating NOS2. In panel c, scanning magnification shows extensive staining of tumor
interstitium. Panel d is a higher magnification detail of panel c that shows heavy staining of mononuclear
cells (small arrows) and endothelial cells (large arrows). Hematoxylin counterstain; original magnifica-
tions: panel a, ×400; panel b, ×630; panel c, ×50; panel d, ×400. NOS2 immunohistochemistry was
performed as described previously (3).
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dothelial cells within the tumors and in
the tumor cells (Fig. 1, B). The decline
in NOS2 activity with advancing tumor
stage may be attributed to the tumor
cell-induced immunosuppression of
NOS2 expression in tumor-infiltrating
mononuclear cells of advanced tumors
(8).
We then determined the p53 mutation
frequency and mutation type in relation
to the NOS2 activity levels in colon tu-
mors. We confined the mutational
analysis to the evolutionarily conserved
region in the p53 gene. This genomic
region contains about 90% of the known
p53 mutations and all of the mutational
hotspots at CpG dinucleotide sites
(9,10). We found 11 mutations among
26 adenomas (mutation frequency 4
34.6%, with one tumor containing three
mutations) and 44 mutations among 92
carcinomas of Dukes’ stages A through
D (mutation frequency 4 47.8%). None
of the carcinomas had multiple muta-
tions. There were 44 missense muta-
tions, six nonsense mutations, two inser-
tions, two deletions, and one inversion.
The predominant mutation was the G:C
to A:T transition at CpG dinucleotides
(n 4 34, mutation frequency 4 61.8%),
and a significant association between
these transitions and increased NOS2
activity was observed when compared
with tumors with other types of muta-
tions, e.g., transversions and frameshift
mutations (P 4 .004; Mann–Whitney U
rank sum test) (see Fig. 2, A). Further
analysis demonstrated a convincing
dose–response relationship between
NOS2 activity and G:C to A:T transi-
tions at CpG dinucleotides in carcino-
mas (P 4 .003; Mantel–Haenszel test
for trend) (Fig. 2, B); the rates of all
other mutations varied inversely with
NOS2 activity.
Most p53 transition mutations in co-
lorectal carcinoma occur at CpG di-
nucleotides that contain 5-methylcyto-
sine (9,10), and our data support the
hypothesis that NOS2 activity generates
the high frequency of G:C to A:T muta-
tions at 5-methylcytosine sites in the
p53 gene. The formation of deaminating
NO intermediates through up-regulation
of NOS2 has been documented (11), and
exposure of Salmonella typhimurium,
plasmid DNA, and the p53 complemen-
tary DNA to NO donors generated
mostly G:C to A:T transitions (12,13).
In addition, the increased formation of
N-nitrosamines in activated macro-
phages (14) and Corynebacterium par-
vum-treated rats (15) indicates that au-
toxidation of endogenously produced
NO leads to electrophilic and nitrosating
agents such as N2O3 in vivo.
Endogenous NO production also
causes oxidative DNA damage (16) as a
result of stoichiometric fluxes of NO
andsuperoxidethatgenerateperoxynitrite
(17). Our observation that detectable ni-
trotyrosine formation is restricted to
only a subset of NOS2-expressing tu-
mor-infiltrating mononuclear cells in
colon tumors (3) suggests that the NO to
peroxynitrite pathway is not a dominant
pathway in adenomas. Peroxynitrite has
also been shown to cause mainly G:C to
T:A and G:C to C:G transversions (18),
which does not match the p53 muta-
tional spectrum of colon tumors with a
predominance of G:C to A:T transition
mutations. However, NO quenches both
superoxide and an oxidizing intermedi-
Fig. 2. Inducible Ca2+-independent nitric oxide synthase (NOS2) activity and
p53 mutations in human colon tumors. A) NOS2 activity is significantly higher
in human colon tumors with G:C to A:T transitions at CpG sites in the p53
gene when compared with that in tumors with mutations at other sites in this
gene (P 4 .004; Mann–Whitney U rank sum test). The specimens include
adenomas, adenomas with carcinoma in situ, and carcinomas of Dukes’ stages
A through D. B) The frequency of G:C to A:T transitions at CpG dinucleotide
sites is positively correlated with NOS2 activity (P 4 .003; Mantel–Haenszel
test for trend). NOS2 activity and p53 mutation frequency and mutation type
were analyzed in 92 colon carcinomas of Dukes’ stages A through D contain-
ing 44 mutations. The NOS2 activity of the 92 carcinomas was divided into
tertiles of the distribution, described as low (undetectable NOS2 activity),
medium (range from 0.1 to 3.5 pmol citrulline/min per milligram protein as the
highest NOS2 activity found in this group), and high (range from 3.7 pmol
citrulline/min per milligram protein as the lowest NOS2 activity found in this
group to 48.8 pmol citrulline/min per milligram protein). The frequency of both
G:C to A:T mutations at CpG dinucleotides and all other mutations is shown
as the percentage of tumors with a mutation for each tertile. The category ‘‘all
other mutations’’ includes transversions, transitions at sites other than CpG,
and frameshift mutations. The frequency of G:C to A:T muta-
tions at CpG dinucleotide sites is highest in the group with high NOS2 activity,
whereas the frequency of all other p53 gene mutations is inversely correlated
with NOS2 activity. For p53 sequencing, paraffin-embedded tumor samples
were dewaxed and microdissected from 50-mm sections. DNA was isolated by
use of sodium dodecyl sulfate/proteinase K treatment and phenol/chloroform
extraction, and the p53 coding sequence was amplified as described previously
(25) and sequenced with the T7 sequenase kit (Amersham Life Science Inc.,
Arlington Heights, IL).
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ate of peroxynitrite (17) and may, there-
fore, protect against superoxide toxicity.
This particular NO chemistry can ex-
plain our finding that NOS2 expression
is inversely correlated with the fre-
quency of mutations other than G:C to
A:T at CpG dinucleotides (Fig. 2, B).
Our investigation of primary human
colon tumors establishes a strong posi-
tive relationship between the presence
of NOS2 in the tumors and the fre-
quency of G:C to A:T transitions at CpG
dinucleotides. These mutations also are
common in lymphoid, esophageal, head
and neck, stomach, brain, and breast
cancers (9,10,19). Increased NOS2 ex-
pression has been demonstrated in four
of these cancers (1–4). Tumor-associ-
ated NO production may modify DNA
directly, or it may inhibit DNA repair
activities (17), such as the recently de-
scribed human thymine–DNA glyco-
sylase, which has been shown to repair
G:T mismatches at CpG dinucleotides
(20). Because NO production also in-
duces accumulation of wild-type p53
(21,22), the resulting growth inhibition
can provide an additional strong selec-
tion pressure for nonfunctional, mutant
p53 (23). NO may, therefore, act as both
an endogenous initiator and a promoter
in human colon carcinogenesis. Specific
inhibitors of NOS2, as demonstrated re-
cently in an animal tumor model (24),
may have important chemopreventive
potential in human colorectal cancer.
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